Browsing Tag
diffuse large B-cell lymphoma
8 posts
How China’s lymphoma treatment landscape could evolve with HMPL-760’s registrational study
Can HMPL-760 reshape lymphoma treatment? Explore HUTCHMED’s Phase III strategy and what it means for BTK competition.
Roche’s Columvi shows durable three-year overall survival edge over Rituxan in phase III STARGLO trial
Find out how Roche’s Columvi delivered a durable three-year survival advantage in the phase III STARGLO lymphoma trial and what it means for patients and investors.
Genentech’s Lunsumio and Polivy combination triples remission in relapsed large B-cell lymphoma
Genentech's chemo-free Lunsumio and Polivy combo tripled remission time in relapsed B-cell lymphoma, signaling a shift toward outpatient oncology treatment.
Merck initiates Phase 3 waveLINE-010 trial for zilovertamab vedotin in diffuse large B-cell lymphoma
Merck, known as MSD outside the United States and Canada, has launched its pivotal Phase 3 waveLINE-010 clinical…
Genmab gets EPKINLY FDA approval for diffuse large B-cell lymphoma
Danish biotech company Genmab has secured accelerated approval for EPKINLY (epcoritamab-bysp) from the US Food and Drug Administration…
Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the…
Gilead Sciences to acquire immuno-oncology company Forty Seven for $4.9bn
Gilead Sciences acquisition of Forty Seven : US biotech company Gilead Sciences has signed an all-cash deal worth…
Denovo Biopharma gets FDA approval to launch phase 2b GBM trial for DB102
Denovo Biopharma has secured approval from the US Food and Drug Administration (FDA) to launch its phase 2b…